The panel thanks Drs Taelman and Muylle for their comments on apheresis in the treatment of overwhelming loiasis and P falciparum malaria. As may be realized, these are diseases not normally encountered in North America, where, with few exceptions, our main attention was directed. However, as noted by Files et al,1 with more frequent travel to endemic areas, increasing numbers of cases may be seen here in the future. The rationale for apheresis in these conditions seems well founded, and we would probably have placed them in category II, conditions in which available evidence tends to favor efficacy. It certainly will be necessary to update the panel's findings and recommendations periodically as additional indications for apheresis are suggested and as new data pertaining to existing indications become available.